Added to YB: 2025-10-07
Pitch date: 2025-10-04
SLNO [bullish]
Soleno Therapeutics, Inc.
-34.51%
current return
Author Info
No bio for this author
Company Info
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Market Cap
$2.1B
Pitch Price
$60.18
Price Target
100.00 (+154%)
Dividend
N/A
EV/EBITDA
-19.25
P/E
-23.79
EV/Sales
15.85
Sector
Biotechnology
Category
growth
Soleno Therapeutics, Inc. Long Idea
SLNO: Only FDA-approved therapy for Prader-Willi hyperphagia, ~$500K/year pricing. Strong launch: Q2 $32.7M revenue vs consensus, 1000+ treatments initiated. Peak sales $1.8B-$2.6B target. Safety concerns overblown vs 3-4% natural PWS mortality. $100 price target in 12-18mo if Q3 beats $46M consensus.
Read full article (2 min)